Walter Zidek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Walter Zidek has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Martin Tepel
Odense University Hospital
7 shared publications Claus Spieker
4 shared publications- Klaus Kisters
Department of Internal Medicine, St. Anna Hospital, Herne, Germany
4 shared publications Michael Barenbrock
3 shared publications- Christoph Hasslacher
St. Josefskrankenhaus Heidelberg, Akademisches Lehrkrankenhaus der Universität Heidelberg
2 shared publications Ernst-Rudolf Krefting
2 shared publications
Latest Publications
- 29 July 2019
- Published by Springer Nature in Der Kardiologe
- Vol. 13 (4) , 239-248
Arterielle Hypertonie bei Menschen mit Diabetes
- 29 July 2019
- Published by Springer Nature in Der Kardiologe
- Vol. 13 (4) , 239-248
Arterielle Hypertonie bei Menschen mit Diabetes
- 4 March 2019
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 161 (4) , 41-42
V. a. hypertensive Krise
- 4 March 2019
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 161 (4) , 41-42
V. a. hypertensive Krise
- 11 January 2019
- Published by Springer Nature in Der Diabetologe
- Vol. 15 (1) , 55-64
Arterielle Hypertonie bei Menschen mit Diabetes
- 11 January 2019
- Published by Springer Nature in Der Diabetologe
- Vol. 15 (1) , 55-64
Arterielle Hypertonie bei Menschen mit Diabetes
- Open Access
- 1 May 2018
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 33 (suppl_1) , i31-i32
FO032HOW CAN WE IDENTIFY REAL VASCULAR DAMAGE BY LONG-TERM PULSE WAVE ANALYSIS
INTRODUCTION AND AIMS: Carotid-femoral pulse wave velocity (cfPWV) is an established non-invasive standard to assess aortic stiffness (AS). It has been shown to be associated with increased cardiovascular mortality and morbidity independent of classic cardiovascular risk factors. However, cfPWV is strongly associated with blood pressure (BP) level. It is thus unknown whether particular measured cfPWV value reflects real vessel damage or current level of BP. Emerging non-invasive oscillometric devices use mathematic approaches and are able to deliver an estimated aortic PWV (eaPWV), which shows good correlation with cfPWV. Such devices allow easy and quick calculation of eaPWV, which can be repeated plenty of times under varying BP and patient position. The aim of the study was to establish an BP-independent eaPWV based on mathematical analysis of 24 hours ambulatory BP and pulse wave (PW) monitoring.
- 1 May 2018
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 33 (suppl_1) , i31-i32
Open AccessFO032HOW CAN WE IDENTIFY REAL VASCULAR DAMAGE BY LONG-TERM PULSE WAVE ANALYSIS
INTRODUCTION AND AIMS: Carotid-femoral pulse wave velocity (cfPWV) is an established non-invasive standard to assess aortic stiffness (AS). It has been shown to be associated with increased cardiovascular mortality and morbidity independent of classic cardiovascular risk factors. However, cfPWV is strongly associated with blood pressure (BP) level. It is thus unknown whether particular measured cfPWV value reflects real vessel damage or current level of BP. Emerging non-invasive oscillometric devices use mathematic approaches and are able to deliver an estimated aortic PWV (eaPWV), which shows good correlation with cfPWV. Such devices allow easy and quick calculation of eaPWV, which can be repeated plenty of times under varying BP and patient position. The aim of the study was to establish an BP-independent eaPWV based on mathematical analysis of 24 hours ambulatory BP and pulse wave (PW) monitoring.
- 25 October 2017
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 159 (18) , 39-42
Blutdrucksenkung zum Schutz der Nieren
- 25 October 2017
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 159 (18) , 39-42
Blutdrucksenkung zum Schutz der Nieren
- 23 February 2015
- Published by Springer Nature in CardioVasc
- Vol. 15 (1) , 41-43
Betablocker nicht Medikament erster Wahl
- 23 February 2015
- Published by Springer Nature in CardioVasc
- Vol. 15 (1) , 41-43
Betablocker nicht Medikament erster Wahl
- 19 November 2014
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 156 (20) , 48-52
Mehr Freiheit bei der Therapiewahl
- 19 November 2014
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 156 (20) , 48-52
Mehr Freiheit bei der Therapiewahl
- Open Access
- 27 October 2014
- Published by Springer Nature in Clinical Proteomics
- Vol. 11 (1) , 1-9
Absolute quantification of endogenous angiotensin II levels in human plasma using ESI-LC-MS/MS
Angiotensin II acts as a peptide hormone and component of renin-angiotensin- system (RAS) regulating the blood pressure, and seems to be involved in renal and vascular disorders. There is no reliable quantification method for angiotensin II available until now and the angiotensin II plasma levels described in the literature are correspondingly strongly divergent. Therefore, we developed and validated a sensitive, selective and reliable LC-ESI-MS/MS method for absolute quantification of angiotensin II concentration in human plasma based on the AQUA strategy. Plasma samples were extracted using MAX Oasis cartridges and were subjected to a further immunoaffinity-purification using immobilized anti-angiotensin II antibodies in order to isolate endogenous angiotensin II. Stable isotope (13C- and 15 N-) labeled angiotensin II was used as an internal standard. The fractionated samples were analysed using LC-ESI-MS/MS. The calibration curve was established in plasma in the concentration range 6–240 pM (r2 > 0.999). The developed and validated method was successfully applied for quantification of endogenous angiotensin II in human plasma of healthy volunteers and chronic kidney disease (CKD-5D) patients. The mean plasma angiotensin II levels were found to be 18.4 ± 3.3 pM in healthy subjects and 64.5 ± 32.4 pM in CKD-5D patients (each n =9). The LC-ESI-MS/MS-based method for quantification of angiotensin II levels in human plasma was successfully evaluated within the study. This method is applicable for clinical applications aiming at the validation of the impact of highly physiologically and pathophysiologically active angiotensin II.
- 27 October 2014
- Published by Springer Nature in Clinical Proteomics
- Vol. 11 (1) , 1-9
Open AccessAbsolute quantification of endogenous angiotensin II levels in human plasma using ESI-LC-MS/MS
Angiotensin II acts as a peptide hormone and component of renin-angiotensin- system (RAS) regulating the blood pressure, and seems to be involved in renal and vascular disorders. There is no reliable quantification method for angiotensin II available until now and the angiotensin II plasma levels described in the literature are correspondingly strongly divergent. Therefore, we developed and validated a sensitive, selective and reliable LC-ESI-MS/MS method for absolute quantification of angiotensin II concentration in human plasma based on the AQUA strategy. Plasma samples were extracted using MAX Oasis cartridges and were subjected to a further immunoaffinity-purification using immobilized anti-angiotensin II antibodies in order to isolate endogenous angiotensin II. Stable isotope (13C- and 15 N-) labeled angiotensin II was used as an internal standard. The fractionated samples were analysed using LC-ESI-MS/MS. The calibration curve was established in plasma in the concentration range 6–240 pM (r2 > 0.999). The developed and validated method was successfully applied for quantification of endogenous angiotensin II in human plasma of healthy volunteers and chronic kidney disease (CKD-5D) patients. The mean plasma angiotensin II levels were found to be 18.4 ± 3.3 pM in healthy subjects and 64.5 ± 32.4 pM in CKD-5D patients (each n =9). The LC-ESI-MS/MS-based method for quantification of angiotensin II levels in human plasma was successfully evaluated within the study. This method is applicable for clinical applications aiming at the validation of the impact of highly physiologically and pathophysiologically active angiotensin II.
- 14 February 2014
- Published by Springer Nature in CardioVasc
- Vol. 14 (1) , 44-46
Nur wenige nichtmedikamentöse Verfahren wirksam
- 14 February 2014
- Published by Springer Nature in CardioVasc
- Vol. 14 (1) , 44-46
Nur wenige nichtmedikamentöse Verfahren wirksam
- 11 June 2013
- Published by Georg Thieme Verlag KG in Aktuelle Kardiologie
- Vol. 2 (03) , 171-176
Pharmakotherapie der arteriellen Hypertonie
Die Indikation zur medikamentösen Behandlung richtet sich neben der Blutdruckhöhe nach dem kardiovaskulären Gesamtrisiko. Antihypertensiva der ersten Wahl sind Diuretika, Betablocker, RAS-Blocker (ACE-Hemmer und AT1-Blocker) und Kalziumantagonisten. In Abhängigkeit vom kardiovaskulären Risiko wird die Behandlung als Monotherapie oder sofort als Kombinationstherapie begonnen. Die Antihypertensiva der zweiten Wahl sind bei Versagen der Medikamente erster Wahl sowie in speziellen klinischen Situationen hilfreich. Bei Versagen der medikamentösen Therapie sind die neueren invasiven Therapieverfahren zu erwägen. The indication for antihypertensive treatment is not only determined by the height of blood pressure but also by the total cardiovascular risk. First-line antihypertensive agents are diuretics, beta blockers, RAS blockers (ACE inhibitors and AT1 blockers) as well as calcium antagonists. Depending on cardiovascular risk treatment is started as monotherapy or directly as combination therapy. Second line antihypertensive drugs may be helpful after first-line antihypertensive drugs failed and in special clinical situations. If drug treatment fails the novel invasive procedures have to be considered for treatment of hypertension.
- 11 June 2013
- Published by Georg Thieme Verlag KG in Aktuelle Kardiologie
- Vol. 2 (03) , 171-176
Pharmakotherapie der arteriellen Hypertonie
Die Indikation zur medikamentösen Behandlung richtet sich neben der Blutdruckhöhe nach dem kardiovaskulären Gesamtrisiko. Antihypertensiva der ersten Wahl sind Diuretika, Betablocker, RAS-Blocker (ACE-Hemmer und AT1-Blocker) und Kalziumantagonisten. In Abhängigkeit vom kardiovaskulären Risiko wird die Behandlung als Monotherapie oder sofort als Kombinationstherapie begonnen. Die Antihypertensiva der zweiten Wahl sind bei Versagen der Medikamente erster Wahl sowie in speziellen klinischen Situationen hilfreich. Bei Versagen der medikamentösen Therapie sind die neueren invasiven Therapieverfahren zu erwägen. The indication for antihypertensive treatment is not only determined by the height of blood pressure but also by the total cardiovascular risk. First-line antihypertensive agents are diuretics, beta blockers, RAS blockers (ACE inhibitors and AT1 blockers) as well as calcium antagonists. Depending on cardiovascular risk treatment is started as monotherapy or directly as combination therapy. Second line antihypertensive drugs may be helpful after first-line antihypertensive drugs failed and in special clinical situations. If drug treatment fails the novel invasive procedures have to be considered for treatment of hypertension.